Non-Invasive Determination of Fetal Chromosome Abnormalities
| Status: | Completed |
|---|---|
| Conditions: | Other Indications, Women's Studies |
| Therapuetic Areas: | Other, Reproductive |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/2/2016 |
| Start Date: | January 2009 |
| End Date: | December 2009 |
The overall significance of this study is to develop a laboratory developed test (LDT) to
use a new marker in the maternal blood to better identify pregnancies that have a child with
a chromosome abnormality such as Down syndrome (trisomy 21), Edward's syndrome (trisomy 18),
Patau syndrome (trisomy 13), Klinefelter syndrome, (47, XXY), and other chromosome
abnormalities. Accomplishing that task would reduce the need for invasive amniocentesis and
CVS procedures.
use a new marker in the maternal blood to better identify pregnancies that have a child with
a chromosome abnormality such as Down syndrome (trisomy 21), Edward's syndrome (trisomy 18),
Patau syndrome (trisomy 13), Klinefelter syndrome, (47, XXY), and other chromosome
abnormalities. Accomplishing that task would reduce the need for invasive amniocentesis and
CVS procedures.
Inclusion Criteria:
- This study is only applicable to women who are between 8 and 30 weeks' gestation and
who have been determined increased risk for fetal aneuploidy. In the interest of
expediting and simplifying this study, the investigators want only women who have
already decided to undergo second-trimester amniocentesis or CVS.
Exclusion Criteria:
- The only exclusion criteria are those mentioned.
We found this trial at
7
sites
Winthrop University Hospital Founded in 1896 by a group of local physicians and concerned citizens,...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials